Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and tourette’s syndrome: Preliminary clinical experience

Phillip B. Chappell, Mark A Riddle, Lawrence Scahill, Kimberly A. Lynch, Robert Schultz, Amy Arnsten, James F. Leckman, Donald J. Cohen

Research output: Contribution to journalArticle


Objective: Many children with Tourette’s syndrome (TS) are handicapped more by difficulties with inattention, impulsivity, and hyperactivity than by their tics. However, stimulant medications used to treat attention-deficit hyperactivity disorder (ADHD) can exacerbate tics. Guanfacine is an α2adrenergic agonist that may have beneficial effects on attention, without the hypotensive or sedative effects of clonidine, which is often used as an alternative to stimulants. Method: An open-label study of guanfacine was performed in 10 children with TS+ADHD, aged 8 to 16 years. The duration of follow-up was 4 to 20 weeks, and the majority of subjects were treated with 1.5 mg/day. Ratings of tic severity and ADHD symptoms were obtained using the Yale Global Tic Severity Scale (YGTSS), the Tic Symptom Self Report (TSSR), and the Conners Parent Rating Scale. In addition, blind Continuous Performance Tests (CPTs) were performed at baseline and at two follow-up intervals in eight subjects. Results: Guanfacine was associated with significant decreases in both commission errors (p

Original languageEnglish (US)
Pages (from-to)1140-1146
Number of pages7
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Issue number9
Publication statusPublished - 1995
Externally publishedYes



  • Attention-deficit hyperactivity disorder
  • Guanfacine
  • Tourette’s syndrome

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this